Marker Therapeutics Inc (MRKR) Quote

ARE WE ALL RICH YET?

july p2, excuse me.
I think it will run earlier in anticipation and/or it doesnt stay single for much longer.

No indications we will see any new data in June.

Like I said, the company needs to be acquired quickly based on inside knowledge the data looks really promising, or it's over current shareholders.

has a loyal buyer. think the june data will make it go, they have outstanding data. Multitarget mutations!

Phantom, Thank You for contacting JV and filling us in. Your timeline for event seems the most reasonable.
I think our main problem is, Nobody has heard of MRKR, Doctors, Patients, Investors.
I have not and will not sell a single share, but I kind of give up trying to figure this price.
3 patients, 2 great news and 1 good news, AND IT DOES BASICALLY NOTHING ???
Have a great summer.

That's always my biggest question also. I don't want to be diluted to hell. Every time I bring it up I get the same answer which is the company fully believes they can make it to the end of 2025 with what they have. I was originally skeptical that they could make it that far but the 10Qs do seem to back them up as they have got their spending in check.

There is a 99% chance we experience some dilution but I previously spoke to Vera about this and he said it would be done on the back of a news release. My guess would be the final lymphoma data which shouldn't be too long. IMO, early next year at the latest but we'll see when we get the enrollment update.

If the results there are not enough to gain som major SP appreciation then the dilution will be the least of our worries.

Thanks. Vera still working on his CEO communication skills I see haha. Big Q for me as with all biotechs is funding, i.e., can they produce enough good data in the near-term to keep going w/o excessive dilution. I can wait til Q4 if the data’s good; if the H2 data lets down or is still too small sample, we could be in trouble, we’ll see.

They're a disaster. Zero energy coming from this company. It feels empty. Without a quick buyout this thing is toast, IMO.

Thanks

I reached out to clarify if we would be getting data in the summer like previously stated or if it would be the "2nd half" of the year which I will generally equate to the latter half of the year. The answer was just 2nd half of the year so I will stick to my assumption that we will get lymphoma data sometime in Q4. My biggest question is if it will be interim or the final readout as I was previously led to believe we could have final data by then. We'll see I guess.

Additionally, I was told they are planning a research event sometime in July where they should provide more updates. Details on that should be provided sometime next month I would assume.

So as of now we have this supposed research event, lymphoma data, and the initiation of the Off the Shelf MT401 AML trial to look forward to for the rest of the year. Always a shot at pancreatic updates but the standard announcement on that is they are waiting for grant funds or other non dilutive funds before initiating so I won't count on that news right now

This company filed a 13g

https://www.nea.com/team?unit=operations#filters

The buyer never really left here and has excellent data, no cytox..

I hope it's just that and not a delay or mediocre results prompting them to keep it quiet

That's my fear is that they will use those two patients as a cop out. Last I spoke with Vera he said there would be a data release over summer inn addition to this 2 patient release. Technically 2nd half of the year could be summer so I hope they stick to it. I'll follow up if I get clarification.

If you do reach out I’d be curious to hear what they say. I suppose technically Vera can say he shared data H1 because we know about those two additional patients, but obviously we were all hoping for more. Slow enrollment might be the culprit; drug seems to be working 🤞 just need to get it to more ppl / stack up the data.

That is the only thing I can think of. I plan on reaching out to see if I can get a clear answer but I don't see any other reason for the delay unless they completely filled the trial and are deciding to just wait until all data is available. I was previously told full trial data should be available by the end of the year.

What could be delaying this now? Slow enrollment?

Thanks, as always

I see that now.... Seems the only hope for sustaining SP short term would be a grant or something else to fund pancreatic

Thank You

They quietly changed data release from 1st half of the year to the 2nd half. At this point I would be surprised if they release any lymphoma data in June and even more surprised if they ever stick to their original timelines.

I think so but not positive. It may just be a rehash of what they just gave us.

Thanks

Aren't we expecting some new data in June?

Cash looks OK also:
Cash Position and Guidance: At March 31, 2024, Marker had cash and cash equivalents of $11.3 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.

It all sounds good so far, 3 patients, 3 for 3 good results.
First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including a relapse within 90 days of anti-CD19 CAR T cell therapy (Breyanzi) (PRESS RELEASE, JUNE 12, 2023). Without prior lymphodepletion, this participant achieved a complete response eight weeks after the second infusion of MT-601 and remains in complete response nine months after initial treatment with MT-601 (PRESS RELEASE, APRIL 8, 2024).
Another study participant had transformed follicular Non-Hodgkin’s Lymphoma (NHL) and failed 12 lines of therapy, including bispecific T cell engager therapy (mosunetuzumab) for follicular NHL, and anti-CD19 CAR T cells (Yescarta) after transformation into DLBCL. At the time of MT-601 infusion, only follicular NHL persisted in this patient. Eight weeks after initial infusion with MT-601 without prior lymphodepletion, the study participant achieved a complete response, which remains three months following treatment with MT-601(PRESS RELEASE, APRIL 8, 2024).
The third study participant treated had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a partial response eight weeks after MT-601 treatment without prior lymphodepletion with all lesions decreasing in size including one that has completely resolved (PRESS RELEASE, APRIL 8, 2024).
Treatment was well tolerated among all patients with no significant treatment-related adverse events including cytokine release syndrome or neurotoxicity.

Press Release:
https://ir.markertherapeutics.com/news-releases/news-release-details/marker-therapeutics-reports-first-quarter-2024-financial-results

How about a buyout instead just to put retail out of their misery.

It would be sure nice to see a little run up before data in June....

CLEAR!!! Still no pulse.

MRKR under $5

Thank You. sounds good ... for now.

Thanks

Getting interesting. 3 out of 3 objective responses (2 CR's and 1 PR). This should get MT-601 out there on the radar in finding more trial participants

https://ir.markertherapeutics.com/news-releases/news-release-details/principal-investigator-city-hope-national-medical-center-invited

PRINCIPAL INVESTIGATOR FROM CITY OF HOPE NATIONAL MEDICAL CENTER INVITED TO PRESENT CLINICAL DATA FROM MARKER THERAPEUTICS APOLLO STUDY AT 11TH GLOBAL SUMMIT ON HEMATOLOGIC MALIGNANCIES

April 8, 2024 at 7:00 AM EDT
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada

Study participants tolerated initial dose level well and demonstrated durable objective responses after MT-601 treatment

Study participant with Non-Hodgkin’s Lymphoma who relapsed after anti-CD19 CAR T cell therapy remains in complete response nine months after MT-601 treatment

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

The Phase 1 APOLLO study is investigating MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Marker previously reported that the first study participant tolerated the treatment well and achieved a complete response (CR) eight weeks after the second infusion of MT-601, which was maintained at the six months follow-up visit (PRESS RELEASE, SEPTEMBER 11, 2023). During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601. This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy. The participant relapsed within 90 days of CAR T cell therapy yet maintained a CR for at least nine months after treatment with MT-601, suggesting that response to MT-601 was more durable compared to CAR T cells in this study participant.

Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope. One of the study participants had transformed follicular NHL and failed a total of 12 lines of therapy including mosunetuzumab (bispecific antibody) for follicular NHL, and Yescarta (anti-CD19 CAR T cell therapy) after transformation into DLBCL. At the time of MT-601 administration, only follicular NHL persisted after the last treatment. Eight weeks after initial infusion with MT-601, this study participant achieved a CR and remains in CR three months following treatment with MT-601. The third patient treated at City of Hope as part of the APOLLO trial presented with DLBCL with cutaneous involvement only and was not eligible for CAR T cell therapy. When evaluated at eight weeks post-treatment, the study participant was in partial response with all lesions decreasing in size including one that has completely resolved.

Dr. Shouse also reported that treatment was well tolerated among all patients with no significant treatment-related adverse events including no reports of cytokine release syndrome (CRS) or immune-effector cell associated neurotoxicity syndrome (ICANS), and that all patients will continue to be monitored closely for long-term treatment effects and durability of response.

“We are encouraged by these clinical results and the potential impact of MT-601 in patients with lymphoma who have relapsed or are ineligible for CAR T cell therapy,” said Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA. "Observing objective responses in three out of three patients with lymphoma treated with MT-601 at our site is a remarkable and gratifying achievement and we are encouraged by the benefits this therapy has provided to our patients. I am honored to have been invited to showcase these data on MT-601 to leading experts in the field at the 11th Global Summit on Hematologic Malignancies.”

The therapeutic potential of MT-601 is further reinforced by non-clinical data demonstrating that MT-601 is able to eradicate lymphoma cells resistant to anti-CD19 CAR T cells (PRESS RELEASE, MAY 31, 2023).

CAR T cell therapy is associated with severe adverse events such as cytokine release syndrome or neurotoxicity, as well as the potential risk of inducing secondary cancers (U.S. FOOD AND DRUG ADMINISTRATION, NOVEMBER 28, 2023). MultiTAA-specific T cell therapies have been well-tolerated in clinical trials to date. Marker believes that multiTAA-specific T cells represent a safe alternative to CAR T cells due to their non-genetically engineered approach that selectively expands tumor-specific T cells from a patient’s/donor’s blood without the risk of mutagenesis.

“Although treatment with CD19-targeting CAR T cells is rapidly expanding among hematological malignancies, 40-60% of patients relapse within one year of therapy,” commented Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics. “The sustained CR for nine months in our first study participant, who relapsed 90 days following CAR T cell treatment, indicates durable efficacy of MT-601 versus CAR T cell therapy in this participant.”

“Though the number of patients treated to date in our APOLLO study is quite small, observing objective responses in all three study participants treated at City of Hope is encouraging, and highlights the potential benefit of MT-601 in patients with lymphoma. We are continuing to enroll additional patients to hopefully reinforce these promising observations and look forward to treating more participants in this Phase 1 study,” concluded Dr. Vera.

Today we announced that one of our Principal Investigators was invited to present his experience from our #APOLLO study in patients with #lymphoma at the 11th Global Summit on Hematologic Malignancies.

For more information: https://t.co/BehXh5Myf2#immunotherapy #multiTAAs pic.twitter.com/HvIrf3coos— Marker Therapeutics, Inc. (@MRKRTherapeutic) April 8, 2024

MRKR under $5

Boo!...You people have no sense of humor. Are you just gonna sit there like sad clowns or get up off your collective a-s and demand answers and management changes?

MT-402?

>>Hope something comes out of MT-401

Thank You. Hope something comes out of MT-401 OTS.

Strange to say this to someone on a message board but I actually believe you. 8

Lol. Not ready for that yet but I promise I will make sure you hear the call.

Thanks. I was afraid you said Rose and I missed it.

I'm having a difficult time understanding how anything like this T product can be effective and just crawl along like this. Feels like the usual Research for researches sake, and good salaries.

Nothing new which was to be expected. Just gave a recap of data we've already seen and reaffirmed the company's financial position. As of the latest release they are still on track to release lymphoma data within the next three months. Hopefully they don't release in Q2 earnings and try to pass it off as "1st half of the year" like they've done in the past.

The only real takeaways here are that Vera is still speaking highly of the lymphoma trial as we are nearing data and they have been in discussions with other pharma companies for a potential partnership. Vera's confidence has not seemed to waver and he is most certainly privy to all the data that we should be getting soon. I would have expected him to tone that down a bit if the data was looking shaky. Obviously, he could just be talking the trial up knowing that giving any hint of failure wouldn't look good but In my conversations with him in the past I don't get this vibe from him. Take that as you will. Like I've said in the past any partnership will require more data. Vera all but confirmed that in the presentation yesterday when asked about potential partnerships. Said they have talked to some other companies but they want to see more data to essentially "de-risk" any investment or partnership. Makes sense and is nothing we didn't already assume.

The lymphoma data that is coming soon seems to be the only thing we have to look forward to for a while. If data impresses the company should be able to have their path forward mapped out by the end of the year but I'm not expecting much else news this year other than that data and them initiating the MT-401 OTS trial which I don't expect to bring much interest until data starts to roll in most likely mid next year at the earliest. He mentioned the grant for the pancreatic trial as well but they don't have anything confirmed right now. If the pancreatic trial moves forward it will be with non-dilutive funding and will not effect the company's current cash runway. I will say, it is nice to see the company finally start taking their finances seriously.

All this being said if the lymphoma data is good it should warrant enough interest to at the very least keep the share price stable. We'll find out in roughly three months.

Yeah, throw in TapImmune and this has been a very long and awful journey.

Dr. Juan.......Please speed things up. Another ten years and I'll be living in an urn.

I suspect Vera's emphasis on "Non-dilutive financing" is his way of saying nobody will do business with us anymore after the nightmare performance.

FISCAL YEAR 2023 FINANCIAL HIGHLIGHTS

Cash Position and Guidance: At December 31, 2023, Marker had cash and cash equivalents of $15.1 million. The Company believes that its existing cash and cash equivalents will fund its operating expenses into the fourth quarter of 2025, inclusive of available drawdowns from grant funds.

R&D Expenses: Research and development expenses were $10.4 million for the year ended December 31, 2023, compared to $12.0 million for the year ended December 31, 2022.

G&A Expenses: General and administrative expenses were $7.5 million for the year ended December 31, 2023, compared to $11.3 million for the year ended December 31, 2022.

Net Loss: Marker reported a net loss of $8.2 million for the year ended December 31, 2023, compared to a net loss of $29.9 million for the year ended December 31, 2022.